References
- Ohshima K, Hirashiki A, Cheng XW, et al. Impact of mild to moderate renal dysfunction on left ventricular relaxation function and prognosis in ambulatory patients with nonischemic dilated cardiomyopathy. Int Heart J. 2011;52(6):366–371. DOI: 10.1536/ihj.52.366
- Liu BC, Tang TT, Lv LL, Lan HY. Renal tubule injury: A driving force toward chronic kidney disease. Kidney Int. 2018;93(3):568–579. DOI: 10.1016/j.kint.2017.09.033
- Inglis SC, Stewart S, Papachan A, et al. Anaemia and renal function in heart failure due to idiopathic dilated cardiomyopathy. Eur J Heart Fail. 2007;9(4):384–390. DOI: 10.1016/j.ejheart.2006.10.013
- Karatolios K, Holzendorf V, Richter A, Schieffer B, Pankuweit S; Competence Network Heart Failure Germany. Long-term outcome and predictors of outcome in patients with non-ischemic dilated cardiomyopathy. Int J Cardiol. 2016;220:608–612. DOI: 10.1016/j.ijcard.2016.06.167
- Lukas Laws J, Lancaster MC, Ben Shoemaker M, et al. Arrhythmias as presentation of genetic cardiomyopathy. Circ Res. 2022;130(11):1698–1722. DOI: 10.1161/CIRCRESAHA.122.319835
- Takahashi A, Shiga T, Shoda M, Manaka T, Ejima K, Hagiwara N. Impact of renal dysfunction on appropriate therapy in implantable cardioverter defibrillator patients with non-ischaemic dilated cardiomyopathy. Europace. 2009;11(11):1476–1482. DOI: 10.1093/europace/eup210
- Kellum JA, Lameire N; KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: A KDIGO summary (Part 1). Crit Care. 2013;17(1):204. DOI: 10.1186/cc11454
- Efthimiou O, Seo M, Chalkou K, Debray T, Egger M, Salanti G. Developing clinical prediction models: A step-by-step guide. BMJ. 2024;386:
e078276 . DOI: 10.1136/bmj-2023-078276 - Gopal DM, Sam F. New and emerging biomarkers in left ventricular systolic dysfunction—insight into dilated cardiomyopathy. J Cardiovasc Transl Res. 2013;6(4):516–527. DOI: 10.1007/s12265-013-9462-3
- Goetze JP, Bruneau BG, Ramos HR, Ogawa T, de Bold MK, de Bold AJ. Cardiac natriuretic peptides. Nat Rev Cardiol. 2020;17(11):698–717. DOI: 10.1038/s41569-020-0381-0
- Wang H, Ran J, Jiang T. Urea. Subcell Biochem. 2014;73:7–29. DOI: 10.1007/978-94-017-9343-8_2
- Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012;380(9843):756–766. DOI: 10.1016/S0140-6736(11)61454-2
- Klein JD, Blount MA, Sands JM. Molecular mechanisms of urea transport in health and disease. Pflugers Arch. 2012;464(6):561–572. DOI: 10.1007/s00424-012-1157-0
- Menon S, Symons JM, Selewski DT. Acute kidney injury. Pediatr Rev. 2023;44(5):265–279. DOI: 10.1542/pir.2021-005438
- Luft FC. Biomarkers and predicting acute kidney injury. Acta Physiol (Oxf). 2021;231(1):
e13479 . DOI: 10.1111/apha.13479 - Sirich TL, Funk BA, Plummer NS, Hostetter TH, Meyer TW. Prominent accumulation in hemodialysis patients of solutes normally cleared by tubular secretion. J Am Soc Nephrol. 2014;25(3):615–622. DOI: 10.1681/ASN.2013060597
- Hall C. NT-ProBNP: The mechanism behind the marker. J Card Fail. 2005;11(5 Suppl):S81–S83. DOI: 10.1016/j.cardfail.2005.04.019
- Pfister R, Diedrichs H, Schiedermair A, et al. Prognostic impact of NT-proBNP and renal function in comparison to contemporary multi-marker risk scores in heart failure patients. Eur J Heart Fail. 2008;10(3):315–320. DOI: 10.1016/j.ejheart.2008.01.009
- Schaub JA, Coca SG, Moledina DG, Gentry M, Testani JM, Parikh CR. Amino-terminal Pro-B-Type natriuretic peptide for diagnosis and prognosis in patients with renal dysfunction: A systematic review and meta-analysis. JACC Heart Fail. 2015;3(12):977–989. DOI: 10.1016/j.jchf.2015.07.014
- Emdin M, Passino C, Prontera C, et al. Comparison of brain natriuretic peptide (BNP) and amino-terminal ProBNP for early diagnosis of heart failure. Clin Chem. 2007;53(7):1289–1297. DOI: 10.1373/clinchem.2006.080234
- Fathallah-Shaykh SA, Cramer MT. Uric acid and the kidney. Pediatr Nephrol. 2014;29(6):999–1008. DOI: 10.1007/s00467-013-2549-x
- Choi HK, Mount DB, Reginato AM; American College of Physicians; American Physiological Society. Pathogenesis of gout. Ann Intern Med. 2005;143(7):499–516. DOI: 10.7326/0003-4819-143-7-200510040-00009
- Li J, Mi S, Wang M, et al. Dynamic LVEF decline and serum NT-proBNP and uric acid levels before heart transplantation are independent predictors of adverse outcomes in young adult patients with dilated cardiomyopathy. Rev Cardiovasc Med. 2024;25(5):153. DOI: 10.31083/j.rcm2505153
- Zharikov S, Krotova K, Hu H, et al. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol. 2008;295(5):C1183–C1190. DOI: 10.1152/ajpcell.00075.2008
- Yang Q, Fu C, Xiao J, Ye Z. Uric acid upregulates the adiponectinadiponectin receptor 1 pathway in renal proximal tubule epithelial cells. Mol Med Rep. 2018;17(3):3545–3554. DOI: 10.3892/mmr.2017.8315
- Su HY, Yang C, Liang D, Liu HF. Research advances in the mechanisms of hyperuricemia-induced renal injury. Biomed Res Int. 2020;2020:5817348. DOI: 10.1155/2020/5817348
- Rizo-Téllez SA, Sekheri M, Filep JG. C-reactive protein: A target for therapy to reduce inflammation. Front Immunol. 2023;14:1237729. DOI: 10.3389/fimmu.2023.1237729
- Zhou HH, Tang YL, Xu TH, Cheng B. C-reactive protein: Structure, function, regulation, and role in clinical diseases. Front Immunol. 2024;15:1425168. DOI: 10.3389/fimmu.2024.1425168
- Zhang R, Zhang YY, Huang XR, et al. C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease. Hypertension. 2010;55(4):953–960. DOI: 10.1161/HYPERTENSIONAHA.109.140608
- Della Corte V, Tuttolomondo A, Pecoraro R, Di Raimondo D, Vassallo V, Pinto A. Inflammation, endothelial dysfunction and arterial stiffness as therapeutic targets in cardiovascular medicine. Curr Pharm Des. 2016;22(30):4658–4668. DOI: 10.2174/1381612822666160510124801
- Plebani M. Why C-reactive protein is one of the most requested tests in clinical laboratories?. Clin Chem Lab Med. 2023;61(9):1540–1545. DOI: 10.1515/cclm-2023-0086
- Wu W, Zhang YP, Pan YM, et al. Predictive value of C-reactive protein/albumin ratio for acute kidney injury in patients with acute pancreatitis. J Inflamm Res. 2024;17:5495–5507. DOI: 10.2147/JIR.S473466
- Tang Y, Huang XR, Lv J, et al. C-reactive protein promotes acute kidney injury by impairing G1/S-dependent tubular epithelium cell regeneration. Clin Sci (Lond). 2014;126(9):645–659. DOI: 10.1042/CS20130471
- Haraldsson B, Nyström J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev. 2008;88(2):451–487. DOI: 10.1152/physrev.00055.2006
- Mueller C, McDonald K, de Boer RA, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715–731. DOI: 10.1002/ejhf.1494
- Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754. DOI: 10.3389/fimmu.2018.00754
- So A, Thorens B. Uric acid transport and disease. J Clin Invest. 2010;120(6):1791–1799. DOI: 10.1172/JCI42344
- Akbari T, Hammersley DJ, May CY, Halliday BP, Prasad SK. The impact of cardio-renal-metabolic profile in dilated cardiomyopathy. Curr Cardiol Rep. 2025;27(1):89. DOI: 10.1007/s11886-025-02241-8
- Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet. 2019;394(10212):1949–1964. DOI: 10.1016/S0140-6736(19)32563-2
- Mazzarotto F, Tayal U, Buchan RJ, et al. Reevaluating the genetic contribution of monogenic dilated cardiomyopathy. Circulation. 2020;141(5):387–398. DOI: 10.1161/CIRCULATIONAHA.119.037661
DOI: https://doi.org/10.5334/gh.1577 | Journal eISSN: 2211-8179
Language: English
Page range: 60 - 60
Submitted on: Oct 15, 2025
Accepted on: Jul 28, 2026
Published on: Aug 14, 2026
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Keywords:
© 2026 Rui Yang, Qiqi Song, Haohan Ma, Yongyang Fan, Shu Lin, Tao Liang, Jian Chen, Ning Tan, Lei Jiang, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.